[
    [
        {
            "time": "2020-10-29",
            "original_text": "药明康德发布2020年第三季度报告。2020Q3收入45.83亿元，较去年增长35.4%，经调整后净利润较去年同期增长44.3%。药明康德2020年第三季度营收增长的主要来源于中国区实验室和合同研发与生产业务 (CDMO)，较去年同期增长38.9%和54.9%。",
            "features": {
                "keywords": [
                    "药明康德",
                    "三季报",
                    "收入增长",
                    "净利润增长",
                    "中国区实验室",
                    "CDMO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德发布2020年第三季度报告。2020Q3收入45.83亿元，较去年增长35.4%，经调整后净利润较去年同期增长44.3%。药明康德2020年第三季度营收增长的主要来源于中国区实验室和合同研发与生产业务 (CDMO)，较去年同期增长38.9%和54.9%。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-29",
            "original_text": "海外客户订单增长等原因，药明康德前三季度营收同比27.34%。",
            "features": {
                "keywords": [
                    "药明康德",
                    "海外客户",
                    "订单增长",
                    "营收增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "海外客户订单增长等原因，药明康德前三季度营收同比27.34%。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-29",
            "original_text": "惠誉：上调药明康德评级展望至正面，并确认其“BBB-”评级。",
            "features": {
                "keywords": [
                    "惠誉",
                    "评级展望",
                    "上调",
                    "正面",
                    "BBB-"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "惠誉：上调药明康德评级展望至正面，并确认其“BBB-”评级。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-29",
            "original_text": "药明康德成功驳回集体诉讼。",
            "features": {
                "keywords": [
                    "药明康德",
                    "集体诉讼",
                    "成功驳回"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德成功驳回集体诉讼。",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-10-29",
            "original_text": "医疗健康-基金3Q分析：三季度医药板块配置比例同比上升 环比下降。",
            "features": {
                "keywords": [
                    "医疗健康",
                    "基金",
                    "医药板块",
                    "配置比例",
                    "同比上升",
                    "环比下降"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "医疗健康-基金3Q分析：三季度医药板块配置比例同比上升 环比下降。",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]